Tilray Brands Reports Record FY26 Revenue of $915M, Guides FY27 Adjusted EBITDA to $68–$75M
TLRY is trading near its 52-week low of $3.8 (8.2% above the low).
Summary
Tilray Brands reported record fiscal 2026 revenue of $915.5 million and record adjusted EBITDA of $61.1 million, and guided fiscal 2027 adjusted EBITDA to $68–$75 million, reflecting double-digit growth and a strengthened balance sheet.
Key Events · Earnings and Guidance · TLRY
-
Record FY26 Revenue and Profitability
Net revenue reached $915.5 million, up 11% YoY, with adjusted EBITDA of $61.1 million, up 11% YoY. Gross profit rose 8% to $260.4 million.
-
FY27 Adjusted EBITDA Guidance of $68–$75M
Management guided fiscal 2027 adjusted EBITDA to $68–$75 million, representing double-digit growth over FY26, driven by continued momentum across all segments.
-
Balance Sheet Strengthened
Net debt reduced to $0.7 million, with approximately $235 million in cash, restricted cash, and marketable securities, providing financial flexibility for strategic investments.
-
International Medical Cannabis Revenue Surges 34%
International medical cannabis revenue grew 34% for the fiscal year, highlighting Tilray's expanding European medical cannabis and pharmaceutical distribution platform.
Analysis · TLRY · Life Sciences
Tilray delivered record fiscal 2026 revenue of $915.5 million, up 11% year-over-year, and record adjusted EBITDA of $61.1 million. The company also issued fiscal 2027 adjusted EBITDA guidance of $68–$75 million, implying double-digit growth. The balance sheet strengthened significantly, with net debt nearly eliminated and $235 million in cash and equivalents. These results demonstrate the diversified platform's ability to generate profitable growth across cannabis, beverage, distribution, and wellness segments, and the guidance provides a concrete profitability target that should support the stock.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 29.2% of the 1496 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TLRY was trading at $4.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $483.6M. The 52-week trading range was $3.80 to $23.20. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.